Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2007 1
2013 1
2015 1
2018 1
2019 1
2021 3
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus.
Goteti K, Garcia R, Gillespie WR, French J, Klopp-Schulze L, Li Y, Mateo CV, Roy S, Guenther O, Benincosa L, Venkatakrishnan K. Goteti K, et al. Among authors: mateo cv. CPT Pharmacometrics Syst Pharmacol. 2024 Feb;13(2):281-295. doi: 10.1002/psp4.13083. Epub 2023 Dec 4. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38050332 Free PMC article.
Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.
Kareva I, Zutshi A, Mateo CV, Papasouliotis O. Kareva I, et al. Among authors: mateo cv. Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):601-611. doi: 10.1007/s13318-021-00706-z. Epub 2021 Jul 30. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34328632 Free PMC article. Review.
Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development.
Goteti K, French J, Garcia R, Li Y, Casset-Semanaz F, Aydemir A, Townsend R, Mateo CV, Studham M, Guenther O, Kao A, Gastonguay M, Girard P, Benincosa L, Venkatakrishnan K. Goteti K, et al. Among authors: mateo cv. CPT Pharmacometrics Syst Pharmacol. 2023 Feb;12(2):180-195. doi: 10.1002/psp4.12888. Epub 2022 Nov 29. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36350330 Free PMC article.
MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding In Vivo Activity against HER2-Expressing Tumors.
Avilés P, Domínguez JM, Guillén MJ, Muñoz-Alonso MJ, Mateo C, Rodriguez-Acebes R, Molina-Guijarro JM, Francesch A, Martínez-Leal JF, Munt S, Galmarini CM, Cuevas C. Avilés P, et al. Among authors: mateo c. Mol Cancer Ther. 2018 Apr;17(4):786-794. doi: 10.1158/1535-7163.MCT-17-0795. Epub 2018 Feb 13. Mol Cancer Ther. 2018. PMID: 29440297
Correction to: Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.
Kareva I, Zutshi A, Mateo CV, Papasouliotis O. Kareva I, et al. Among authors: mateo cv. Eur J Drug Metab Pharmacokinet. 2021 Nov;46(6):827. doi: 10.1007/s13318-021-00719-8. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34581976 Free PMC article. No abstract available.
Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
Tardy C, Facompré M, Laine W, Baldeyrou B, García-Gravalos D, Francesch A, Mateo C, Pastor A, Jiménez JA, Manzanares I, Cuevas C, Bailly C. Tardy C, et al. Among authors: mateo c. Bioorg Med Chem. 2004 Apr 1;12(7):1697-712. doi: 10.1016/j.bmc.2004.01.020. Bioorg Med Chem. 2004. PMID: 15028262
13 results